NVS and NOVN Related Headlines
Go Back- Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Trea
- New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
- Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis
- FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies
- Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
- Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
- Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
- Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
- Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
- FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases
- Novartis (NVS) Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution, 100 mg/mL due to Crystallization
- Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
- Earnings wave, Novartis guidance, ARK's Twitter stake - what's moving markets
- Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
- Novartis (NVS) announces FDA approves expanded indication for Leqvio
- US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
- Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease
- KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
- Sandoz Canada improves patients’ access to treatment with the launch of three new generics
- Ligand Reports First Quarter 2023 Financial Results
- European stocks lower; UBS weakens after profit slump
- Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
NVS and NOVN Related Press Releases
Go Back- Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Trea
- New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
- Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis
- FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies
- Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
- Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
- Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
- Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
- Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
- FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases
- Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
- Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
- US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
- Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease
- KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
- Sandoz Canada improves patients’ access to treatment with the launch of three new generics
- Ligand Reports First Quarter 2023 Financial Results
- Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
NVS and NOVN Related SEC Filings
Go Back- Form S-8 POS NOVARTIS AG
- Form SC 13G/A NOVARTIS AG Filed by: BlackRock Inc.
- Form 6-K NOVARTIS AG For: Dec 31
- Form 6-K NOVARTIS AG For: Dec 31
- Form IRANNOTICE NOVARTIS AG
- Form 20-F NOVARTIS AG For: Dec 31
- Form 6-K NOVARTIS AG For: Jan 08
- Form 6-K NOVARTIS AG For: Dec 11
- Form 6-K NOVARTIS AG For: Dec 05
- Form 6-K NOVARTIS AG For: Nov 28
- Form 6-K NOVARTIS AG For: Oct 30
- Form 6-K NOVARTIS AG For: Sep 30
- Form 6-K NOVARTIS AG For: Oct 04
- Form 6-K NOVARTIS AG For: Oct 02
- Form 144 NOVARTIS AG Filed by: Kowalski Robert William
- Form 6-K NOVARTIS AG For: Sep 05
- Form 6-K NOVARTIS AG For: Aug 18
- Form 6-K NOVARTIS AG For: Aug 09
- Form 6-K NOVARTIS AG For: Jun 30
- Form 6-K NOVARTIS AG For: Jul 07
- Form 6-K NOVARTIS AG For: Jun 12
- Form SD NOVARTIS AG
- Form 20-F/A NOVARTIS AG For: Dec 31
- Form 6-K NOVARTIS AG For: Mar 31
